We further investigated the effect of the inhibitors on the clonogenic potential of an additional 12 primary samples from patients with AML, 7 of which had a DNMT3A mutation (Fig. 5d), whereas the other 5 were DNMT3A wild type (WT; Extended Data Fig. 7a–c). This evidence concerns the gene DNMT3A and acute myeloid leukemia.